Drug or dietary treatments were started or planned in 10 children. been made 77 months earlier than occurred in this study. It is suggested that initial diagnostic evaluation Cefoxitin sodium of children with NDD should include trio WGS or WES, with extension of accelerated sequencing modalities to high-acuity patients. == INTRODUCTION == Neurodevelopmental disorders (NDDs), including intellectual disability, global developmental delay, and autism, affect more than 3% of children. Etiologic identification of NDD often engenders a lengthy and costly differential diagnostic odyssey without return of a definitive diagnosis (1). The current etiologic evaluation of NDD is complex: primary tests include neuroimaging, karyotype, array comparative genome hybridization (array CGH) and/or single-nucleotide polymorphism arrays, and phenotype-driven metabolic, molecular, and serial gene sequencing studies. Secondary, invasive tests, such as biopsies, cerebrospinal fluid examination, and electromyography, enable diagnosis in a small percentage of additional cases. About Cefoxitin sodium 30% of NDDs are attributable to structural genetic variation, but more than half of patients do not receive an etiologic diagnosis (15). Single-gene testing for diagnosis of NDD is especially challenging because of profound locus heterogeneity and overlapping symptoms (610). As predicted, the introduction of whole-genome sequencing (WGS) and whole-exome sequencing (WES) into medical practice has begun to transform the diagnosis and management of patients with genetic disease (11). Acceleration and simplification of genetic diagnosis are a result of the following: (i) multiplexed testing to interrogate nearly all genes on a physicians differential at a cost and turnaround time approaching that of a single-gene test; (ii) Cefoxitin sodium the ability to analyze genes for which no other test exists; and (iii) the capacity to cast a wide net that can detect pathogenic variants in genes not yet on the clinicians differential. The latter proves particularly powerful for diagnosing patients with rare or newly discovered genetic diseases (12) and for patients with atypical or incomplete clinical presentations (13). Furthermore, new gene and phenotype discovery has increasingly become part of the diagnostic process. The importance of molecular diagnosis is that care of such patients can then shift from interim, phenotypic-driven management to definitive treatment that is refined by genotype (11). Although early reports indicate that WES enables diagnosis of neurologic disorders (9,14,15), the clinical and cost-effectiveness are not known. Data are needed to guideline best-practice recommendations concerning screening of probands (affected individuals) only versus trios (proband plus parents), use of WES versus WGS, and the appropriate prioritization of genomic screening in an etiologic evaluation for numerous medical presentations. Herein, we statement the effectiveness of a WGS and WES sequencing system for children with NDD, featuring an accelerated sequencing modality for individuals with high-acuity illness. We format diagnostic yield and an initial analysis of the impact on time to analysis, cost of diagnostic screening, and subsequent medical care. == RESULTS == == Characteristics of enrolled individuals == A biorepository was founded at a childrens hospital in the central United States for family members with one or more children suspected of having a monogenetic disease, but without a definitive analysis (16). Over a 33-month period, 155 family members with heterogeneous medical conditions were enrolled into the repository and analyzed by WGS or WES for diagnostic evaluation. Of these, 100 family members had 119 children with NDDs and were Srebf1 the subjects of the analysis reported herein (Table 1). Standard WES or quick WGS was performed on the basis of acuity of illness (16): 85 family members with affected children adopted in ambulatory clinics received non-expedited WES, followed by non-expedited WGS if WES was unrevealing; 15 family members with infants who have been symptomatic at or shortly after birth and in neonatal rigorous care models (NICUs) or pediatric rigorous care models (PICUs) received immediate, quick WGS (Table 1). The mean age of the affected children in the ambulatory medical center group was about 7 years at enrollment (Table 2). Symptoms were apparent at an average of less than 1 year of age in most children (Table 2). The medical features of each affected child were ascertained by examination of electronic health records and communication with treating clinicians and translated into Human being Phenotype Ontology (HPO) terms (17). The most common features.
Drug or dietary treatments were started or planned in 10 children